Brokerages Set Sionna Therapeutics, Inc. (NASDAQ:SION) Price Target at $45.43

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) have earned an average rating of “Moderate Buy” from the nine ratings firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $45.4286.

Several analysts have commented on SION shares. BTIG Research reissued a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a report on Wednesday, January 14th. Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Lifesci Capital initiated coverage on shares of Sionna Therapeutics in a report on Tuesday, December 23rd. They issued an “outperform” rating and a $60.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 29th. Finally, Royal Bank Of Canada restated an “underperform” rating and set a $24.00 price target on shares of Sionna Therapeutics in a report on Monday, December 1st.

Sionna Therapeutics Trading Down 7.1%

Shares of NASDAQ SION opened at $41.31 on Friday. The company has a 50 day simple moving average of $41.40 and a two-hundred day simple moving average of $32.80. The stock has a market cap of $1.84 billion and a price-to-earnings ratio of -8.48. Sionna Therapeutics has a 12 month low of $7.26 and a 12 month high of $45.00.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06.

Insider Buying and Selling at Sionna Therapeutics

In other Sionna Therapeutics news, Director Peter A. Thompson sold 29,063 shares of the business’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $44.58, for a total transaction of $1,295,628.54. Following the sale, the director directly owned 3,530,702 shares in the company, valued at approximately $157,398,695.16. The trade was a 0.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Tpg Gp A, Llc sold 250,000 shares of the company’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $40.00, for a total value of $10,000,000.00. Following the completion of the sale, the insider owned 6,494,962 shares in the company, valued at $259,798,480. This represents a 3.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 765,181 shares of company stock valued at $32,227,643 in the last ninety days. Insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SION. GF Fund Management CO. LTD. acquired a new position in shares of Sionna Therapeutics in the 4th quarter valued at approximately $36,000. Russell Investments Group Ltd. acquired a new stake in Sionna Therapeutics in the 3rd quarter valued at approximately $30,000. BNP Paribas Financial Markets bought a new position in Sionna Therapeutics in the 2nd quarter valued at about $31,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Sionna Therapeutics in the fourth quarter worth approximately $89,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in Sionna Therapeutics in the second quarter worth about $45,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.